Syngene attempts a base after a prolonged decline

is trading near ₹386 after an extended decline that has pushed the stock close to its recent base. The chart shows a persistent pattern of lower highs through much of the year, followed by a modest bounce from the ₹350–360 region. That rebound has improved the immediate tone, but price remains within a broader downtrend until it can recover the prior swing zones above ₹400 and ₹420. Connors RSI has lifted to about 63.99 from weaker readings, signalling that short-term price behaviour, streak momentum and the recent rate-of-change component have improved together. The reading is constructive without being in the classic overbought zone above 70. However, Connors RSI is designed to identify short-term momentum extremes; by itself, it does not overturn the larger sequence of lower highs visible on the price chart. The key support area is ₹360–350. A close below it would negate the present stabilisation and extend the lower-low pattern. On the upside, ₹400 is the first level where sellers may reappear, followed by ₹420–430, which marked earlier breakdown points. Syngene’s research-services business gives it a differentiated healthcare positioning, yet the technical work is unfinished. The constructive scenario requires the stock to defend ₹360, form higher lows, and reclaim ₹400 with follow-through. Until that sequence develops, the move from ₹350 looks like a relief bounce inside a larger corrective trend rather than a confirmed change in direction.